Literature DB >> 16989913

Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer.

Laurence Guldner1, Nadia Haddy, François Pein, Ibrahima Diallo, Akthar Shamsaldin, Michel Dahan, Jérome Lebidois, Pascal Merlet, Elisabeth Villain, Daniel Sidi, Olivia Sakiroglu, Olivier Hartmann, Dimitri Leftakopoulos, Florent de Vathaire.   

Abstract

PURPOSE: To determine the cardiac status in children 15 years (yrs) or more after a solid tumour treatment. PATIENTS AND METHODS: Of the 447 patients, 229 were fully studied and 218 were not. The following cardiac evaluation was proposed to all the 447 consecutive patients: (1) cardiac Doppler US by one of two expert cardiologists; (2) cardiac rhythm and conduction abnormalities including 24-h holter ECG; (3) (131)I-mIBG myocardial scintigraphy; (4) serum brain natriuretic peptide levels at rest; (5) an exercise test with VO(2)max measurement. The radiation dose delivered to 7 points in the heart was estimated for all patients who had received radiotherapy.
RESULTS: Cardiac disorder was diagnosed in 89 evaluated patients (39%) including 24 heart failures and 65 other asymptomatic cardiac diseases. When adjusting on potential confounders, cardiac disorder and cardiac failure risks were respectively linear (ERR at 1 Gy: 26%) and linear-quadratic (ERR at 1 Gy: 19%) functions of the average radiation dose received to the heart. No interaction between cumulative dose of adriamycin and average radiation dose was evidenced for cardiac disorders, but the ERR/Gy of cardiac failure was higher for patients receiving less than 350 mg/m(2) of Adriamycin.
CONCLUSION: Long term heart pathologies are probably one of the major iatrogenic risks encored by patients who survived a childhood cancer. This study strongly emphasizes the need to limit the heart irradiation during radiotherapy, particularly, for patients who also received or were susceptible to later received adriamycin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989913     DOI: 10.1016/j.radonc.2006.08.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Impact of dose calculation models on radiotherapy outcomes and quality adjusted life years for lung cancer treatment: do we need to measure radiotherapy outcomes to tune the radiobiological parameters of a normal tissue complication probability model?

Authors:  Abdulhamid Chaikh; Nicolas Docquière; Pierre-Yves Bondiau; Jacques Balosso
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 2.  Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Saro H Armenian; Melissa M Hudson; Renee L Mulder; Ming Hui Chen; Louis S Constine; Mary Dwyer; Paul C Nathan; Wim J E Tissing; Sadhna Shankar; Elske Sieswerda; Rod Skinner; Julia Steinberger; Elvira C van Dalen; Helena van der Pal; W Hamish Wallace; Gill Levitt; Leontien C M Kremer
Journal:  Lancet Oncol       Date:  2015-03       Impact factor: 41.316

Review 3.  Radiation-Induced Cardiovascular Disease.

Authors:  Deepa Raghunathan; Misha Iftikhar Khilji; Saamir A Hassan; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2017-05       Impact factor: 5.113

4.  Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.

Authors:  Gregory T Armstrong; Vijaya M Joshi; Kirsten K Ness; Thomas H Marwick; Nan Zhang; DeoKumar Srivastava; Brian P Griffin; Richard A Grimm; James Thomas; Dermot Phelan; Patrick Collier; Kevin R Krull; Daniel A Mulrooney; Daniel M Green; Melissa M Hudson; Leslie L Robison; Juan Carlos Plana
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

5.  Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure.

Authors:  F Lennie Wong; Smita Bhatia; Wendy Landier; Liton Francisco; Wendy Leisenring; Melissa M Hudson; Gregory T Armstrong; Ann Mertens; Marilyn Stovall; Leslie L Robison; Gary H Lyman; Steven E Lipshultz; Saro H Armenian
Journal:  Ann Intern Med       Date:  2014-05-20       Impact factor: 25.391

6.  Cardiac-Sparing Whole Lung IMRT in Patients With Pediatric Tumors and Lung Metastasis: Final Report of a Prospective Multicenter Clinical Trial.

Authors:  John A Kalapurakal; Mahesh Gopalakrishnan; David O Walterhouse; Cynthia K Rigsby; Alfred Rademaker; Irene Helenowski; Sandy Kessel; Karen Morano; Fran Laurie; Ken Ulin; Natia Esiashvili; Howard Katzenstein; Karen Marcus; David S Followill; Suzanne L Wolden; Anita Mahajan; Thomas J Fitzgerald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-29       Impact factor: 7.038

7.  Adverse health events and late mortality after pediatric allogeneic hematopoietic SCT-two decades of longitudinal follow-up.

Authors:  M Wilhelmsson; A Vatanen; B Borgström; B Gustafsson; M Taskinen; U M Saarinen-Pihkala; J Winiarski; K Jahnukainen
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

8.  Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy.

Authors:  Rui Zhang; Rebecca M Howell; Kenneth Homann; Annelise Giebeler; Phillip J Taddei; Anita Mahajan; Wayne D Newhauser
Journal:  Radiat Oncol       Date:  2013-07-23       Impact factor: 3.481

9.  A New Proton Therapy Solution Provides Superior Cardiac Sparing Compared With Photon Therapy in Whole Lung Irradiation for Pediatric Tumor Patients.

Authors:  Xue Sha; Jinghao Duan; Xiutong Lin; Jian Zhu; Ruohui Zhang; Tao Sun; Hui Wang; Xiangjuan Meng; Yong Yin
Journal:  Front Oncol       Date:  2021-02-02       Impact factor: 6.244

10.  Enhanced sensitivity to low dose irradiation of ApoE-/- mice mediated by early pro-inflammatory profile and delayed activation of the TGFβ1 cascade involved in fibrogenesis.

Authors:  Virginie Monceau; Lydia Meziani; Carine Strup-Perrot; Eric Morel; Magret Schmidt; Julia Haagen; Brigitte Escoubet; Wolfgang Dörr; Marie-Catherine Vozenin
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.